Found 285 clinical trials
Immune modification of psoriasis by selective IL-23 blockade using risankizumab
Researchers at The Rockefeller University Hospital are conducting a study to explore long-term disease remission of psoriasis with short-term treatment with Risankizumab (SKYRIZITM) - an FDA approved medication for moderate-to-severe psoriasis.
- 0 views
- 06 Apr, 2021
- 1 location
An investigational biologic medication for the treatment of uncontrolled hives despite antihistamine use.
5 Clinic visits over 40 weeks testing a self injected investigational medication versus placebo for the treatment of uncontrolled hives despite antihistamines. You will remain on your current antihistamines while in the study.
- 29 views
- 23 Nov, 2020
- 1 location
AEWS07B1: Collecting and Storing Biological Samples From Patients with Ewing Sarcoma
AEWS07B1: Collecting and Storing Biological Samples From Patients with Ewing Sarcoma
- 60 views
- 08 Nov, 2020
- 1 location
Immunogenicity and Safety Study of GSK Biologicals' Priorix® Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s MMR Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life
Immunogenicity and Safety Study of GSK Biologicals' Priorix® Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s MMR Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life
- 266 views
- 08 Nov, 2020
- 1 location
Prospective Collection of Biological Samples from Subjects with Airway and Lung Diseases for Research
Prospective Collection of Biological samples from subjects with airway and lung diseases for research.
- 65 views
- 11 Jun, 2020
- 1 location
Efficacy and Safety of TY027 a Treatment for COVID-19 in Humans
development. Tychan's TY027, a fully engineered human IgG, is one of the first few biologics in the world, specifically targeting SARS-CoV-2, to enter human clinical trials. Preliminary data from our phase 1
- 0 views
- 26 Jan, 2021
- 1 location
Study to Assess Effectiveness of GlaxoSmithKline's (GSK's) Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults.
The purpose of this study is to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety will also …
- 0 views
- 01 May, 2021
- 101 locations
Study to Assess the Immunogenicity and Safety of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18 years of age.
- 0 views
- 08 Apr, 2021
- 16 locations
Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies
To access to good quality biological samples is a prerequisite for high level translational research. The BIG-RENAPE study has been established by the French hyperthermic intraperitoneal chemotherapy centers involved in the management of peritoneal surface malignancies. The main BIG-RENAPE study aim is to create a large multicentric and prospective repository …
- 1 views
- 23 Jan, 2021
- 1 location
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
- 0 views
- 04 Jun, 2021
- 1 location